NCT00354068View on ClinicalTrials.gov

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

PHASE1CompletedINTERVENTIONAL

Enrollment

65

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

imatinib mesylate

DRUG

temozolomide

OTHER

pharmacological study

Trial Locations (1)

27710

Duke Cancer Institute, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00354068 - Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma | Biotech Hunter | Biotech Hunter